1. Scrip
  2. >>Conferences
  3. >>ASCO

BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients

Company Unveils Phase II/III Relatlimab Combo Data At ASCO

 
• By Alaric DeArment

Data show better safety than Opdivo/Yervoy, though what appears to be slightly lower efficacy, in first-line metastatic or unresectable melanoma.

Sun screen
BMS' anti-LAG3 antibody shows safety benefit combined with Opdivo compared with Opdivo/Yervoy • Source: Shutterstock

The first look at the numbers behind Bristol Myers Squibb Company’s immuno-oncology doublet combination of its anti-LAG3 antibody relatlimab and its PD-1 inhibitor Opdivo (nivolumab) show a combination that is less toxic than the combination of Opdivo with BMS’s CTLA-4 inhibitor Yervoy (ipilimumab), but also seems possibly slightly less effective. However, as the PD-1/LAG3 pairing was significantly more effective than Opdivo monotherapy it has the potential to address a significant population.

The company announced on 19 May data from the Phase II/III RELATIVITY-047 trial testing the two drugs administered as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By Mandy Jackson

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.